Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Provided By GlobeNewswire
Last update: Sep 23, 2024
16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors
Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach
Read more at globenewswire.com
